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ABSTRACT
Introduction Heavy drinkers in contact with alcohol 
services do not routinely have access to testing to 
establish the severity of potential liver disease. Transient 
elastography by FibroScan can provide this information. A 
recent systematic review suggested providing feedback 
to patients based on markers of liver injury can be an 
effective way to reduce harmful alcohol intake. This 
randomised control trial (RCT) aims to establish the 
feasibility of conducting a larger national trial to test the 
effectiveness of FibroScan advice and Alcohol Recovery 
Video Stories (ARVS) in changing high- risk drinking 
behaviour in community alcohol services common to UK 
practice.
Methods and analysis This feasibility trial consists of 
three work packages (WP). WP1: To draft a standardised 
script for FibroScan operators to deliver liver disease- 
specific advice to eligible participants having FibroScan. 
WP2: To create a video library of ARVS for use in the 
feasibility RCT (WP3). WP3: To test the feasibility of the trial 
design, including the FibroScan script and video stories 
developed in WP1 and WP2 in a one- to- one individual 
randomised trial in community alcohol services. Semi- 
structured interviews will be conducted at 6 months 
follow- up for qualitative evaluation. Outcomes will be 
measures of the feasibility of conducting a larger RCT. 
These outcomes will relate to: participant recruitment and 
follow- up, intervention delivery, including the use of the 
Knowledge of LIver Fibrosis Affects Drinking trial FibroScan 
scripts and videos, clinical outcomes, and the acceptability 
and experience of the intervention and trial- related 
procedures. Data analysis will primarily be descriptive 
to address the feasibility aims of the trial. All proposed 
analyses will be documented in a Statistical Analysis Plan.
Ethics and dissemination This trial received favourable 
ethical approval from the West of Scotland Research Ethics 
Service (WoSRES) on 20 January 2021, REC reference: 20/
WS/0179. Results will be submitted for publication to a 
peer- reviewed journal.
Trial registration number ISRCTN16922410.
INTRODUCTION
Alcohol- related liver disease (ARLD) is the 
most common cause of cirrhosis in the UK, 
and mortality from ARLD has risen signifi-
cantly over the past three decades. It is now 
the second most common cause of working 
life years lost in men and fifth in women.1 2 
Europe has one of the highest prevalence of 
Alcohol Use Disorders (AUD), involving 15% 
of men and 3.5% of women.2 Around 25% 
of the UK population drink above the UK 
recommended level of 14 units per week, and 
10% are harmful drinkers.3 The UK’s total per 
capita pure alcohol intake for people age ≥15 
years is 11.4 L/annum per person, which 
is twice the global average of 6.4 L/annum 
per person.2 3 Approximately 20%–30% of 
lifelong drinkers develop liver cirrhosis, and 
the risk is even higher (35%) among harmful 
drinkers.4 5
ARLD causes no symptoms in its earlier 
stages; indeed, patients are often unaware 
they have serious physical health problems 
until they present with the complications 
of cirrhosis, for example; ascites, jaundice, 
Strengths and limitations of this study
 ► The Knowledge of LIver Fibrosis Affects Drinking 
(KLIFAD) trial is the first randomised control trial to 
evaluate the feasibility of using non- invasive liver 
stiffness measurement and alcohol recovery video 
stories as a behavioural intervention.
 ► The mixed- methods design of the KLIFAD trial will 
enable us to test the acceptability of trial- specific 
procedures to participants and key alcohol workers.
 ► The KLIFAD trial will enable a definitive trial to estab-
lish the effectiveness of non- invasive screening for 
liver fibrosis in community alcohol services.
 ► The primary limitation of the KLIFAD trial is that it is 
a single- centre trial which could limit the generali-
sation of findings.
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encephalopathy, variceal bleed and liver failure, when 
the opportunity for treatment and recovery of liver 
health is significantly reduced.1 5 6 It is estimated that 
the cost to the UK of alcohol on health is £3.5 billion per 
year,3 7 consuming 3.6% of the National Health Service 
(NHS) annual budget.8 In England, there were 5698 
alcohol- specific deaths in 2018, the alcohol- specific age- 
standardised death rate was 11.9/100 000 (male=16.4 
female=7.6). Nottingham (UK) has one of the highest 
(total=18.6, male=26.8 and female 10.2) alcohol- specific 
age- standardised death rate/100 000 in the country.9 A 
recent trial from the USA predicted a 75% increase in 
age- standardised annual mortality and a 65% increase in 
decompensated cirrhosis due to ARLD over the next two 
decades.10
Systematic reviews of randomised controlled trials 
(RCTs) have established that delivering brief advice 
about alcohol to harmful drinkers helps them reduce 
their alcohol consumption.11 12 Most studies were 
conducted in primary care settings where the prev-
alence of liver disease is likely to be markedly lower 
than in specialist alcohol treatment services. In alcohol 
services, where high levels of physical and psychological 
dependence on alcohol are frequent, National Institute 
of Clinical Excellence guidelines state adults with high 
levels of alcohol dependency should be assessed and 
offered intensive structured community- based interven-
tions (with or without medical therapy) as these provide 
the best chance of achieving and maintaining absti-
nence from alcohol.13 Most clinical services in the UK 
are based on these principles. Individual programmes 
vary by locality with many of these services delivered by 
non- NHS providers. Despite the delivery of brief advice 
and other alcohol- related interventions in clinical prac-
tice for over two decades, mortality and morbidity due 
to alcohol misuse continues to rise in the UK.3 There 
is a pressing need to optimise existing interventions to 
reduce harmful alcohol intake and examine effective 
alternative options.
Early diagnosis of liver fibrosis provides an opportunity 
to intervene and reduce or stop alcohol intake. This is 
known to be the most effective way of preventing liver 
disease progression.14 Transient elastography by Fibro-
Scan (Echosens, France) has been used in primary care 
(General Practice) settings to detect liver disease in 
populations identified as having liver disease risk (heavy 
drinkers and those with type 2 diabetes). These studies 
showed that screening asymptomatic individuals based on 
risk for liver disease doubles the rates of liver cirrhosis 
diagnosis in the primary care populations studied.15 16 
Moreover, a recent systematic review suggested providing 
feedback to patients based on markers of liver injury can 
be an effective way to reduce harmful alcohol intake.17 
Access to recovery stories can help address mental health 
problems and support recovery from addiction.18 19 Peer 
support from people who have recovered from alcohol 
misuse is beneficial in modifying high risk drinking 
behaviour.20
This trial aims to investigate the feasibility and accept-
ability of conducting an RCT in community specialist 
alcohol services settings run by Nottingham Recovery 
Network (NRN) and to test the acceptability of trial inter-
ventions (FibroScan and Alcohol Recovery Video Stories, 
ARVS).
Selection of the term ‘alcohol misuse’
We acknowledge the heterogeneity in language used to 
describe alcohol use, and also the stigma associated with 
some commonly used terms, which itself can act as barrier 
to change.21 Some terms, such as alcohol use Disorder 
(AUD), are not well understood in the general popula-
tion. The concept for this feasibility trial was developed in 
collaboration with Patient and Public Involvement (PPI) 
groups. After extensive discussion between the study 
team and PPI groups, we have opted for the term ‘alcohol 
misuse’ as a general term to cover excess alcohol intake, 
harmful alcohol intake, drinking problems, alcohol 
dependence, and AUD.
We define alcohol misuse as ‘weekly alcohol intake ≥14 
units, or an Alcohol Use Disorder Identification Test 
(AUDIT) score of ≥8, or key alcohol worker and/or physi-
cian diagnosis or referral from any other services with 
problem drinking’.
The other definitions relevant to Knowledge of LIver 
Fibrosis Affects Drinking (KLIFAD) trial are provided in 
online supplemental material 1 (SP- Definitions).
METHODS AND ANALYSIS
KLIFAD is a parallel design feasibility RCT. The trial 
will be conducted in a single centre in the UK, carried 
out at three community alcohol services in Nottingham 
(the Wellbeing Hub, Edwin House and the Primary Care 
Alcohol Clinic run by the NRN) hosted by Framework 
and NRN and working in partnership with Nottingham-
shire NHS Foundation Trust.
The KLIFAD trial consists of three work packages (WP) 
(figure 1).
Work package one (WP1)
WP1 aims to design a standardised script framework for 
FibroScan operators to deliver liver disease- specific advice 
to participants having FibroScan as part of the feasibility 
RCT (WP3).
FibroScan, is an ultrasound technology developed by 
Echosence, France, which non- invasively asseses liver stiff-
ness. A prototype script for FibroScan has been created 
in consultation with the existing KLIFAD PPI group 
covering three ranges of FibroScan scores, normal ≤7 
Kilopascal (kPa), intermediate fibrosis 8–15 kPa and 
advance fibrosis ≥15 kPa. online supplemental material 1 
The trial flow chart for WP1 is provided in figure 2.
We will organise separate participant and FibroScan 
operator focus groups to collect feedback on the proto-
type scripts. The participant focus group will allow us to 
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and feedback, as well as considering how best to present 
the FibroScan results (eg, graphically, in the text). The 
FibroScan operator focus group will specifically discuss 
implementation in clinical practice. In addition, to 
evaluate the stage of change that each participant has 
reached, a validated readiness to change model will be 
piloted.22
Following Krueger’s (1988) focus group guide, each 
focus group will include five to eight participants and will 
last for a maximum of 2 hours.23 Depending on the latest 
COVID- 19 guidelines, the focus group will be either virtual 
or face- to- face. A topic guide will be used (SP- Focus Group 
Guide WP1 V.2.0). We aim to arrange two participant focus 
groups and one FibroScan operator focus group. The focus 
groups will be facilitated by two members of the research 
team. Examples of questions include: (a) If you were a 
participant in the trial, would the script make sense to you? 
(b) Are there any parts of the script that you do not under-
stand, and if so, why? (c) What is the best way to present 
the results of the FibroScan (eg, graphically, in the text)?
Figure 1 The KLIFAD trial timeline and flow chart. The trial has three work packages (WP), WP3 is in randomised feasibility 
trial. AUDIT, Alcohol Use Disorder Identification Test; GCP, good clinical practice; KLIFAD, Knowledge of LIver Fibrosis Affects 
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Eligible participants (table 1) will be identified and 
recruited through multiple channels. For example, via 
existing patient forums at all three recruitment settings, 
the KLIFAD PPI group, by offering information to patients 
self- presenting to any of the trial treatment settings, snow-
ball methods and via Black, Asian and minority ethnicity/
Framework PPI groups. The focus group meeting will be 
recorded and transcribed verbatim either by automated 
Figure 2 Flow diagram for; work package one to create FibroScan scripted feedback and work package two to create alcohol 
recovery videos stories. KLIFAD, Knowledge of LIver Fibrosis Affects Drinking; NEON, narrative experiences online; PPI, patient 
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software or an independent sponsor- approved transcriber. 
After the first participant focus group, the FibroScan 
script will be edited considering feedback and a second 
focus group will then be held to review iterated scripts. 
The final scripts will be sent via email to participants of 
focus groups for any final thoughts. We will then organise 
a FibroScan operator focus group of key alcohol workers 
working at any of the recruitment settings who are willing 
to give informed consent, to discuss any specific imple-
mentation issues.
After the focus groups, we will collect participant feed-
back on the change model (SP- Change Model Ques-
tionnaire (CMQ) V.1.0) to get an initial sense of the 
applicability of readiness to change following discussion 
about the scripts.
Work package two (WP2)
WP2 aims to create a video library of ARVS from people 
with a history of alcohol misuse. These ARVS will be used 
in the feasibility RCT (WP3).
Receiving mental health recovery stories can provide 
benefits to some people experiencing mental health 
distress,18 24 25 and the effectiveness of mental health 
recovery stories as an intervention to increase quality of 
life has been examined in a clinical trial.26 However, equiv-
alent evidence is not available for the impact of ARVS. So 
that we can explore the impact of stories of recovery from 
alcohol misuse, in WP2 we will develop a set of recovery 
stories from participants who have successfully overcome 
their alcohol misuse. These videos will be peer- reviewed 
by the KLIFAD PPI group which will include input from 
Nottingham University Hospitals NHS Trust (NUH) 
Black, Asian and minority Ethnic PPI group. Based on 
feedback, the videos will then be edited ready for use in 
the feasibility RCT (WP3). All edits will be agreed on with 
the story narrators.
For each narrator, we will follow their preference to 
create either:
 ► A recovery story that starts with an open- ended ques-
tion where narrators have the liberty to tell their story 
without interruption or
 ► A recovery story in which the participant is asked a set 
of standard questions.
Drinking history and last FibroScan reading will be 
included at the start of each video. Eligible participants 
(table 1) will be recruited through the channels used in 
WP1. Those who took part in WP1 will also be invited to 
take part in WP2. A purposive sample based on demo-
graphic and liver disease severity of six to nine individ-
uals will be selected.27 We will arrange a meeting with 
the KLIFAD PPI group to discuss what makes a video 
impactful. The outline of WP2 is given in figure 2.
The ARVS will be recorded either at Nottingham 
Digestive Diseases Biomedical Research Centre (NDDC) 
Biomedical Research Centre Nottingham University 
Hospital, the University of Nottingham or the partic-
ipant’s usual place of residence. Each video will be of 
2–5 min duration. Videos will be titled based on Fibro-
Scan score (low- risk, medium and high- risk score). Videos 
will be subtitled and depending on the final video format, 
after the feedback, we envisage adding a photograph 
of the storyteller and a short- associated text on the title 
page with informed consent from the participant. The 
video stories will be brought together in a single- tablet 
computer- based package from which the participant 
will be able to choose their most preferred video after 
receiving a FibroScan score. Collaborative work between 
a clinician and patient can make a significant impact on 
Table 1 KLIFAD trial eligibility criteria
Inclusion criteria Exclusion criteria
Work package one
  A person age ≥18 years Other primary substance 
misuse even where 
alcohol is a factor
  Primary problem of alcohol 
misuse‡
Lacks capacity to 
confirm consent
  Had FibroScan in past
  Work package two
  A person age ≥18 years Lacks capacity to 
confirm consent
  Primary problem of alcohol 
misuse
  Had FibroScan in past
  A person with lived experience 
of alcohol problems
  A person willing to consent to 
the recording and public use of 
their video recording
Work package three: the randomisation phase
  A person age ≥18 years Other primary substance 
misuse even where 
alcohol is a factor
  Primary problem of alcohol 
misuse
Lacks capacity to 
confirm consent
  Referrals from driving 
offences and student 
referrals*
  Out of area clients at 
Edwin House†
  Participants unable 
to comply with trial 
procedures
*As these individuals are essentially not self- presenting, may have 
different motivation and have lower overall levels of alcohol use 
and so are substantially lower risk of having liver disease.
†In whom we cannot obtain follow- up data due to lack of follow- up 
availability.
‡Alcohol misuse was defined as, weekly alcohol intake ≥14 units, 
or an AUDIT score of ≥ 8, or key alcohol worker and/or physician 
diagnosis or referral from any other services with problem drinking.
AUDIT, Alcohol Use Disorder Identification Test; KLIFAD, 
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the recovery process28 and hence in some videos, and with 
consent by narrators, we will include sections of a video 
narrated by a clinician the narrator has worked with.
All video stories recorded as part of the KLIFAD trial 
will have peer review by the trial team and KLIFAD/
Black, Asian and ethnic minority PPI groups. The videos 
will be shown in the same format that they would be used 
in WP3.
Work package 3 (WP3): feasibility RCT
A feasibility RCT of parallel groups (one- to- one) will 
compare usual care (assessment and entry into an alcohol 
reduction programme which does not include informa-
tion on liver disease severity) to usual care plus feedback 
from the FibroScan and ARVS. The eligibility for WP3 is 
provided in table 1 and the attached flow chart (figure 3).
Objectives
Bowen et al’s guide for feasibility studies was used to 
decide objectives.29
1. Test: the intervention (FibroScan plus feedback and 
ARVS) in a feasibility RCT.
2. Acceptability: of feasibility RCT- related procedures and 
interventions among patients and healthcare workers.
3. Feasibility outcomes: to establish recruitment rate, con-
sent rate, dropout rate and completion rate for accu-
rate sample size calculation for future large- scale RCT.
Figure 3 Flow diagram for work- package- three, the randomised control trial flow chart. Work package three is feasibility 
randomised control trial. AUDIT, Alcohol Use Disorder Identification Test; GCP, good clinical practice; KLIFAD, Knowledge of 
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4. Refine: the eligibility and randomisation criteria for a 
future large- scale RCT.
5. Implementation and practicality: to assess the ability of 
community alcohol services to deliver the interven-
tion, and training and support needs for community 
alcohol services keyworkers for delivering the interven-
tion.
6. Adaptation: of KLIFAD trial interventions, FibroScan 
feedback and ARVS format and access as per sugges-
tions from participants and key alcohol workers
7. Limited efficacy: to test limited efficacy of KLIFAD 
interventions
Intervention group
Participants randomised to the intervention arm will 
receive a FibroScan, feedback on FibroScan results and 
watch ARVS immediately after. The ARVS will be made 
available should a participant wish to watch them later.
Control group
Participants randomised to the control arm will continue 
with standard treatment (usual care) provided at the 
three treatment settings. The participants in this arm will 
be offered FibroScan at 6 months.
As part of standard treatment, the recruitment settings 
provide different types of interventions to participants 
in line with the National Drug Treatment Monitoring 
System Data set (NDTMS) and Public Health England 
(PHE) guidelines.30 Existing treatment programmes can 
run for up to 12 weeks.
For adult drug and alcohol services, there are three 
main categories of standard intervention (usual care) 
delivered by the NRN: (a) Psychological: which includes 
motivational interventions, family and social network 
interventions and cognitive and behavioural- based 
relapse prevention interventions (substance misuse 
specific). (b) Recovery support: which includes 12- step 
work and counselling.
(c) Pharmacological: which involves prescribing medica-
tion for drug and/or alcohol relapse prevention support. 
For example, naltrexone, acamprosate, disulfiram as 
part of alcohol or opioid relapse prevention therapy and 
Chlordiazepoxide for acute alcohol withdrawal.
Specific treatment programmes are started after an 
initial assessment and based on the participant’s needs. 
The duration of contact with services varies, most partici-
pants stay with services for 12 weeks, some get discharged 
early and a few stay longer than 6 months.
Methods
Sample size
As this is a feasibility trial, a formal sample size calculation 
for between- group comparisons of a primary outcome 
is not appropriate. Researchers have previously recom-
mended sample sizes between 24 and 50 to satisfactorily 
achieve feasibility outcomes.31–33
After discussion with community alcohol services data 
manager and considering variation in number of patients 
presenting per week, we aim to approach 40 eligible 
participants per month. Assuming a 50% consent rate, we 
anticipate randomising 20 participants per month (10 per 
month per arm) for a recruitment period of 6 months. 
With an estimated sample size of 120, we will be able to 
calculate a dropout rate of 80% within a 95% CI of±7.1%. 
Assuming a non- differential follow- rate of 80%, this target 
sample size should provide follow- up outcome data on a 
minimum of 48 participants in each of the two arms.
Randomisation
The participants will be individually allocated on a one- 
to- one ratio using minimisation with a probabilistic element. 
The minimisation variables will be age, gender, ethnicity and 
severity of alcohol misuse based on the Severity of Alcohol 
Dependence Questionnaire (SADQ) score. To minimise 
selection bias, the randomisation will be externally performed 
by a data manager from NRN.
Schedule of visits
Baseline
The baseline visit will be on the day when the participant 
starts standard treatment at any recruitment setting. At this 
visit, written informed consent will be given by participants 
and participants will be randomised to the intervention or 
control group. Participants in both arms will have an initial 
detailed assessment (SP- NRN assessment form online 
supplemental material 2) as part of their standard care. This 
includes the collection of baseline demographic and clinical 
data (eg, age, gender, ethnicity). Participants randomised to 
the control arm will continue with usual care, while partici-
pants randomised to the intervention arm will have the usual 
care and FibroScan followed by standardised script feedback 
with ARVS watched immediately after the FibroScan result.
Three months
This visit will be part of usual care, no research specific 
activity will be carried out. The research data will be 
extracted from routinely collected data from three treat-
ment settings.
Six months
This will be a telephone consultation or in- person 
appointment by the research team. Participants in the 
control arm will be offered a FibroScan after completion 
of outcomes. The 6- month follow- up is specifically to 
cover those who were lost to follow- up at NRN from the 
treatment programme.
A detailed schedule of the visits is given in table 2.
Data collection
At baseline, 3 and 6 months, the following data will be 
collected (table 2)
 ► Demographics (including address, email address and 
contact number).
This will be archived and kept separate from the main 
database.
 ► AUDIT scores.
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 ► Self- reported alcohol intake (gram and unit per 
week).
 ► Substance misuse other than alcohol.
 ► Breath alcohol testing where participants are still 
attending.
Breath alcohol testing is a strength of this trial; most 
studies have relied on self- reporting of alcohol intake. 
This means we can correlate breath alcohol readings 
with self- reported alcohol consumption, providing 
substantial additional information.
 ► Data on feasibility outcomes (eg, screening rate, 
recruitment rate retention rate).
All the above measurements are part of routine 
outcome data collected by all three recruitment settings, 
apart from the 6- month data collected for those who are 
no longer in a treatment programme at 6 months. All 
three services included in this trial record all of the above 
outcomes as part of the 12- week programme standard 
data set and report these to commissioners. Follow- up 
data are obtained at every attendance and includes the 
above data set and breath alcohol testing.
Qualitative data
We will conduct one- to- one semi- structured interviews 
to evaluate participant’s experiences of being part of the 
trial (eg, ‘Overall, how do you feel about taking part in 
the KLIFAD trial?’) and any changes they may have made 
to their lives (eg, ‘Do you think the KLIFAD trial changed 
your use of alcohol in any way?’). The preliminary quali-
tative interview schedule topic guide is provided in online 
supplemental material 1 (SP: qualitative interview guide). 
It will be piloted before use by the PPI group to check 
structure and wording of questions. A readiness to change 
model used in WP1 will also be piloted. Focus groups and 
interviews will be audio- recorded and transcribed by an 
independent transcriber approved by the sponsor, to 
enable thematic analysis.
Health economics
Routine NHS data collected for the standard care 
12- week treatment programmes will be used together 
with resources utilisation derived from the NHS digital 
linked data to derive healthcare costs and the potential 
benefits of the intervention.
Outcomes
The outcomes are designed to assess the feasibility and 
acceptability of the KLIFAD intervention and research 
processes to help inform a future large- scale RCT. The 
following outcomes will be reported:
 ► Recruitment rate.
 ► Retention rate.
 ► Consent rate.
 ► Acceptability of the intervention (FibroScan and 
ARVS).
 ► The willingness of participants to be randomised to 
trial arms.
 ► Acceptability of the intervention to patients.
 ► Participant adherence.
 ► Feasibility of outcome measures.
These feasibility outcomes will enable the trial team to:
 ► Determine the best primary endpoint for the future 
definitive trial.
Table 2 Work- package- three (feasibility RCT) schedule of 









  Date and time Yes Yes Yes
  Baseline consent Yes – –
  FibroScan+feedback – – Yes
  Watching video stories – – Yes
  Qualitative interview – – Yes
  Demographics Yes – –
  AUDIT score Yes Yes Yes
  SADQ score Yes Yes Yes
  Self- reported alcohol 
intake‡
Yes Yes Yes
  Breath alcohol test Yes Yes Yes
  Substance misuse other 
than alcohol
Yes Yes Yes




  Date and time Yes Yes Yes
  Baseline consent Yes – –
  FibroScan+feedback Yes – –
  Watching video stories Yes – –
  Qualitative interview – – Yes
  Demographics Yes – –
  AUDIT score Yes Yes Yes
  SADQ score Yes Yes Yes
  Self- reported alcohol 
intake
Yes Yes Yes
  Breath alcohol test Yes Yes Yes
  Substance misuse other 
than alcohol
Yes Yes Yes
  Data on feasibility 
outcomes
Yes Yes Yes
*3- months visit: this will be routine visit no trial- specific procedure 
will be carried out.
†6- months visit: will be a telephone consultation and/or if possible/
required in person. The participant in the control group will be 
offered a FibroScan at 6 months if they attend it will be in- person 
appointment.
‡Self- reported alcohol intake in gram and units per week.
AUDIT, Alcohol Use Disorder Identification Test; RCT, randomised 
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 ► Provide sample size estimates for the future definitive 
trial.
 ► Record ARVS which will contribute to the video 
library used in a later large- scale RCT.
Statistical and data analysis plan
The analyses of the quantitative data will be in line with 
Consolidated Standards of Reporting Trials guidelines 
for pilot and feasibility trials.34 Sekhon et al’s frame-
work for acceptability testing will be used.35 The primary 
descriptive analyses will be on an intention- to- treat basis 
(ie, participants are analysed in the group to which they 
were originally allocated). Data will be summarised using 
frequency (%), mean (SD) or median (IQR) depending 
on the distribution of the data. Summary measures will 
be presented along with their 95% CIs whenever appro-
priate. Results of the data analysis will be presented using 
appropriate tables and graphs.
The trial is not powered to investigate statistical signif-
icance between the two arms. As this is a feasibility trial, 
no subgroup analysis is planned. However, the results of 
the feasibility variables will be presented by categories 
of different variables (age, gender, ethnicity severity of 
alcohol misuse).
Different techniques will be followed to maximise the 
completeness of data collection (eg, via staff training). 
The level of missing data will be assessed. This is espe-
cially useful for the proposed primary outcome variables. 
An interim analysis is not planned for this trial, but the 
progress of the trial will be reported to the oversight 
committee who can assess any concerns.
Thematic analysis of qualitative data will be conducted 
following Braun and Clarke’s standard methods.36 Care 
will be taken to integrate updated guidelines about 
thematic analysis including a transparent appreciation 
of researcher reflexivity.36 If the trial management group 
feel the analysis requires external validity, a sample of 
transcripts identified by a random number generator with 
the codebook will be given to a researcher independent 
of the trial. This will allow us to calculate the % agree-
ment and Cohen’s Kappa value (using criteria by Cohen, 
1960).37 The Consolidated Criteria for Reporting Qualita-
tive Studies will be used to ensure thorough and explicit 




The trial received favourable ethical approval from the 
West of Scotland Research Ethics Service (WoSRES) on 
20 January 2021, REC reference: 20/WS/0179.
Informed consent
All participants will provide a written or online (e- con-
sent) informed consent before any research activities 
are initiated. A patient infomation sheet (PIS) written 
in plain language will be provided and it will be ensured 
the participant has understood the trial information and 
had enough time to make an informed decision. The 
Site Investigator will be available to answer any questions 
about trial participation.
Data handling and record-keeping
In compliance with the ICH/Good Clinical Practice 
guidelines, regulations and following the Nottingham-
shire Healthcare NHS Foundation Trust SoPS, the Chief 
or local Principal Investigator will maintain all records 
and documents regarding the conduct of the trial. These 
will be retained for at least 24 months or for longer if 
required. If the responsible investigator is no longer able 
to maintain the trial records, a second person will be 
nominated to take over this responsibility. The routinely 
collected clinical data will be treated in the same way 
as other clinical case records are treated in the NHS 
following relevant policies developed by Nottinghamshire 
Healthcare NHS Foundation Trust, the UK Government 
and the National Institute for Health Research (NIHR).
The Trial Master File and trial documents held by 
the Chief Investigator on behalf of the Sponsor shall be 
finally archived at secure archive facilities at the NDDC 
at Nottingham University Hospital NHS Trust (NUHT). 
This archive shall include all trial databases and associ-
ated meta- data encryption codes.
An index will be created for Case Report Forms and 
paper trial data before storage. All online and IT- based 
data will be password protected and access will only be 
granted to people directly involved in trial and data anal-
ysis. All patient identifiable data will be pseudonymised 
with a trial- specific participant number.
The information will be copied to the research database 
(REDCAP cloud) run by the NUHT. We will delete any 
information that identifies participants by the end of the 
KLIFAD trial (currently expected October 2022). All rele-
vant UK data protection laws will be followed, including 
the 2018 Data Protection Act.
Participant safety
There is a risk that being given a normal FibroScan result 
may provide false reassurance and encourage participants 
to maintain their current level of harmful drinking or 
encourage them to drink more. It is also possible that a 
high reading will generate anxiety. The trial is designed 
to minimise these risks by providing scripted feedback 
(WP1) and watching ARVS (WP2).
Cirrhosis diagnosis and FibroScan: It is anticipated that 
a small number of people will be identified who have 
previously unknown cirrhosis and so would be at risk of 
complications of liver disease. This will be mitigated by 
offering onward referral to out- patient Hepatology for all 
participants with a FibroScan reading >15 kPa. This will 
be via contact with the participant’s GP and would follow 
the current NUHT Nottinghamshire adult liver disease 
stratification pathway for referral.39 Some risk mitigations 
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For WP1 and WP2, we cannot foresee any potential 
risks except possible emotional distress during participa-
tion in a focus group or semi- structured interview. Partic-
ipants can choose to skip any question that they prefer 
not to answer. If distress occurs during the WP3 trial visit, 
we will ask the participant to take a break to recover, or 
they can choose to terminate the process. We do not 
expect that the trial will cause any discomfort or pose any 
disadvantages, however, contact details for the trial team 
are provided should the participant have any questions 
before, during or after taking part. We have also provided 
a list of locally relevant support services at the end of each 
patient information sheet, which participants can consult.
Patient and public involvement (PPI)
The trial has a dedicated PPI group and has considerable 
regular input from the PPI group at every stage of the 
study.
Dissemination
The results of the feasibility trial will be submitted for 
publication to a peer- reviewed journal and presented 
at relevant conferences. A separate manuscript on the 
qualitative aspect of the trial will be written as well. This 
work is part of a PhD for the lead author (MS) who will 
present and submit data as a PhD thesis to the University 
of Nottingham. The work will also be made available to 
trial participants via the NDDC Biomedical Research Unit 
website.
Author affiliations
1Nottingham Digestive Diseases Biomedical Research Centre (NDDC), School of 
Medicine, University of Nottingham, Nottingham, UK
2NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals 
NHS Trust and the University of Nottingham, Nottingham, UK
3Academic Unit of Mental Health and Clinical Neuroscience, School of Medicine, 
C24 Institute of Mental Health, University of Nottingham, Nottingham, UK
4Nottingham Clinical Trials Research Unit, University of Nottingham, Nottingham, UK
5School of Health Sciences,Institute of Mental Health, University of Nottingham, 
Nottingham, UK
6Division of Epidemiology and Public Health, University of Nottingham, Nottingham, 
UK
7School of Medicine, University of Nottingham, Nottingham, UK
Twitter Mohsan Subhani @MohsenSubhani
Contributors MS: KLIFAD trial: The project is part of PhD thesis. Trial coordinator 
and member of trial management group. He has and will contribute to following; 
research idea, funding application, PPI meetings, trial protocol, IRAS application and 
ethical approval, FibroScan training, site initiation, work package 1 focus group, 
work package 2 alcohol recovery story recording, monthly trial management group 
meeting, monitoring ongoing progress of work package 3, qualitative interview, 
data synthesis and analysis, report writing, dissemination. Manuscript: written 
initial draft of the protocol, implemented changes and drafted final version of 
protocol and manuscript. KAJ: KLIFAD trial: member of trial management group. 
She is supervising the qualitative component of the trial including conducting 
and analysing semi- structured interviews. Manuscript: reviewed protocol and 
manuscript, provided specialist input for qualitative aspects of the protocol and 
contributed to the final manuscript. KS: KLIFAD trial: member of trial management 
group. She contributed to following; research idea, funding application, trial 
protocol, IRAS application, work package 3 initiation, trial management and 
progress. Manuscript: reviewed protocol and manuscript and contributed to the 
final manuscript. SR- E: KLIFAD trial: member of trial management group. He 
is supervising work package 2 including proposal for alcohol recovery stories 
recording, editing and finalising. Manuscript: Reviewed protocol and manuscript, 
provided specialist input for work- package- 2 of protocol and contributed to 
final manuscript. HK: KLIFAD trial: member of trial management group. She is 
contributing to work package 1 including developing FibroScan results feedback 
scripts and organising focus groups. Manuscript: reviewed protocol and manuscript, 
provided specialist input for work- package- 1 of protocol and contributed to final 
manuscript. JRM: KLIFAD trial: Member of trial management group. She PhD 
supervisor for Dr Subhani, supervising trial overall and specifically helping with 
health economics part of trial. Manuscript: reviewed protocol and manuscript, 
provided specialist input for health economics section of protocol and contributed 
to final manuscript. DE: KLIFAD trial: member of trial management group. He is 
statistical support for the trial. Manuscript: reviewed final manuscript. AW: KLIFAD 
trial: patient and public involvement coordinator.Manuscript: reviewed final 
manuscript. SDR: KLIFAD trial: Chief investigator, PhD supervisor for Dr Subhani 
and member of trial management group. He has contributed to following; research 
idea, funding application, PPI meetings, trial protocol, IRAS application and ethical 
approval, overall supervision of all three work packages, data synthesis and 
analysis, report writing, dissemination. Manuscript: reviewed final manuscript
Funding This work was supported by 'National Institute for Health Research 
(NIHR)' grant number (RfPB NIHR201146). JRM receives salary support from a 
Medical Research Council Clinician Scientist award (grant number MR/P008348/1).
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Data are available on reasonable request. The 
anonymised data that will support the findings of this trial will be available from the 
corresponding author MS upon reasonable request.
Supplemental material This content has been supplied by the author(s). It has 
not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been 
peer- reviewed. Any opinions or recommendations discussed are solely those 
of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and 
responsibility arising from any reliance placed on the content. Where the content 
includes any translated material, BMJ does not warrant the accuracy and reliability 
of the translations (including but not limited to local regulations, clinical guidelines, 
terminology, drug names and drug dosages), and is not responsible for any error 
and/or omissions arising from translation and adaptation or otherwise.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
ORCID iDs
Mohsan Subhani http:// orcid. org/ 0000- 0001- 8739- 7263
Kirsty Sprange http:// orcid. org/ 0000- 0001- 6443- 7242
Holly Knight http:// orcid. org/ 0000- 0002- 4602- 3238
REFERENCES
 1 Williams R, Aithal G, Alexander GJ, et al. Unacceptable failures: the 
final report of the lancet commission into liver disease in the UK. 
Lancet 2020;395:226–39.
 2 World Health Organisation (WHO). 2018 global STATs report 
on alcohol and health, 2018. Available: https://www. who. int/ 
publications/ i/ item/ 9789241565639 [Accessed 01 Jul 2021].
 3 Williams R, Aspinall R, Bellis M, et al. Addressing liver disease in the 
UK: a blueprint for attaining excellence in health care and reducing 
premature mortality from lifestyle issues of excess consumption of 
alcohol, obesity, and viral hepatitis. Lancet 2014;384:1953–97.
 4 Osna NA, Donohue TM, Kharbanda KK. Alcoholic liver 
disease: pathogenesis and current management. Alcohol Res 
2017;38:147–61.
 5 British liver trust. The- alarming- impact- of- liver- disease, 2019. 
Available: https://www. britishlivertrust. org. uk/ wp- content/ uploads/ 
The- alarming- impact- of- liver- disease- FINAL- June- 2019. pdf 
[Accessed 01 Jul 2021].
 6 Parker R. The natural history of alcohol- related liver disease. Curr 
Opin Gastroenterol 2020;36:164–8.
 7 Public Health England (PHE). Statistics on alcohol, England 2019 
















pen: first published as 10.1136/bm






11Subhani M, et al. BMJ Open 2021;11:e054954. doi:10.1136/bmjopen-2021-054954
Open access
publications/statistical/statistics-on-alcohol/2019 [Accessed 01 Jul 
2021].
 8 House of Commons Health Committee. Government’s alcohol 
strategy. third report of session, 2012. Available: https:// publications. 
parliament. uk/ pa/ cm201213/ cmselect/ cmhealth/ 132/ 132. pdf 
[Accessed 01 Jul 2021].
 9 Public Health England (PHE). Statistics on alcohol, England 2020, 
2020. Available: https://www. gov. uk/ government/ statistics/ statistics- 
on- alcohol- england- 2020 [Accessed 01 Jul 2021].
 10 Julien J, Ayer T, Bethea ED, et al. Projected prevalence and mortality 
associated with alcohol- related liver disease in the USA, 2019- 40: a 
modelling study. Lancet Public Health 2020;5:e316–23.
 11 O'Donnell A, Anderson P, Newbury- Birch D, et al. The impact of brief 
alcohol interventions in primary healthcare: a systematic review of 
reviews. Alcohol Alcohol 2014;49:66–78.
 12 Kaner EFS, Dickinson HO, Beyer FR, et al. Effectiveness of brief 
alcohol interventions in primary care populations. Cochrane 
Database Syst Rev 2007;36:Cd004148.
 13 The National Institue fro Health and Care Excellence (NICE). Alcohol- 
use disorders: prevention, 2010. Available: https://www. nice. org. uk/ 
guidance/ ph24 [Accessed 15 Jul 2021].
 14 Roberts SE, John A, Brown J, et al. Early and late mortality following 
unscheduled admissions for severe liver disease across England and 
Wales. Aliment Pharmacol Ther 2019;49:1334–45.
 15 Harman DJ, Ryder SD, James MW, et al. Direct targeting of risk 
factors significantly increases the detection of liver cirrhosis in 
primary care: a cross- sectional diagnostic study utilising transient 
elastography. BMJ Open 2015;5:e007516.
 16 Harman DJ, Ryder SD, James MW, et al. Obesity and type 2 diabetes 
are important risk factors underlying previously undiagnosed 
cirrhosis in general practice: a cross- sectional study using transient 
elastography. Aliment Pharmacol Ther 2018;47:504–15.
 17 Subhani M, Knight H, Ryder S. Does advice based on biomarkers 
of liver injury or non- invasive tests of liver fibrosis impact high- risk 
drinking behaviour: a systematic review with meta- analysis. Alcohol 
and Alcoholism 2021;56.
 18 Rennick- Egglestone S, Ramsay A, McGranahan R, et al. The impact 
of mental health recovery narratives on recipients experiencing 
mental health problems: qualitative analysis and change model. 
PLoS One 2019;14:e0226201.
 19 White WL. Addiction recovery: its definition and conceptual 
boundaries. J Subst Abuse Treat 2007;33:229–41.
 20 Tracy K, Wallace SP. Benefits of peer support groups in the treatment 
of addiction. Subst Abuse Rehabil 2016;7:143–54.
 21 Ashford RD, Brown AM, Curtis B. Substance use, recovery, and 
linguistics: the impact of word choice on explicit and implicit bias. 
Drug Alcohol Depend 2018;189:131–8.
 22 Zimmerman GL, Olsen CG, Bosworth MF. A 'stages of change' 
approach to helping patients change behavior. Am Fam Physician 
2000;61:1409–16.
 23 Krueger RA. Focus groups: a practical guide for applied research. 
Thousand Oaks, CA, US: Sage Publications, Inc, 1988.
 24 Rennick- Egglestone S, Morgan K, Llewellyn- Beardsley J, et al. 
Mental health recovery narratives and their impact on recipients: 
systematic review and narrative synthesis. Can J Psychiatry 
2019;64:070674371984610–79.
 25 Ng F, Charles A, Pollock K, et al. The mechanisms and processes 
of connection: developing a causal chain model capturing impacts 
of receiving recorded mental health recovery narratives. BMC 
Psychiatry 2019;19:413.
 26 Rennick- Egglestone S, Elliott R, Smuk M, et al. Impact of receiving 
recorded mental health recovery narratives on quality of life in 
people experiencing psychosis, people experiencing other mental 
health problems and for informal carers: narrative experiences online 
(neon) study protocol for three randomised controlled trials. Trials 
2020;21:661.
 27 Charles Teddlie FY. Mixed methods sampling a typology with 
examples. Journal of Mixed Methods Research 2007;1 https://www. 
semanticscholar. org/ paper/ Mixed- Methods- Sampling- A- Typology- 
With- Examples- Teddlie- Yu/ 2f84 250d 22bc c15f dda7 4a2f 878e 67ab 
0e67483e
 28 Stotland NL, Mattson MG, Bergeson S. The recovery concept: 
clinician and consumer perspectives. J Psychiatr Pract 2008;14 
Suppl 2:45–54.
 29 Bowen DJ, Kreuter M, Spring B, et al. How we design feasibility 
studies. Am J Prev Med 2009;36:452–7.
 30 Public helath England (PHE). The International evidence on the 
prevention of drug and alcohol use summary and examples 
of implementation in England, 2015. Available: https:// assets. 
publishing. service. gov. uk/ government/ uploads/ system/ uploads/ 
attachment_ data/ file/ 774743/ Preventing_ drug_ and_ alcohol_ 
misuse__ international_ evidence_ and_ implementation_ examples. pdf 
[Accessed 15 Jul 2021].
 31 Sim J, Lewis M. The size of a pilot study for a clinical trial should be 
calculated in relation to considerations of precision and efficiency. J 
Clin Epidemiol 2012;65:301–8.
 32 Lancaster GA, Dodd S, Williamson PR. Design and analysis of 
pilot studies: recommendations for good practice. J Eval Clin Pract 
2004;10:307–12.
 33 Browne RH. On the use of a pilot sample for sample size 
determination. Stat Med 1995;14:1933–40.
 34 Consolidated Standards of Reporting Trials (CONSORT). Consort 
statement, 2010. Available: http://www. consort- statement. org/ 
[Accessed 01 Jul 2021].
 35 Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare 
interventions: an overview of reviews and development of a 
theoretical framework. BMC Health Serv Res 2017;17:88.
 36 Braun V, Clarke V. Reflecting on reflexive thematic analysis. Qual Res 
Sport Exerc Health 2019;11:589–97.
 37 Cohen J. A coefficient of agreement for nominal scales. Educ 
Psychol Meas 1960;20:37–46.
 38 Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting 
qualitative research (COREQ): a 32- item checklist for interviews and 
focus groups. Int J Qual Health Care 2007;19:349–57.
 39 Chalmers J, Wilkes E, Harris R, et al. The development and 
implementation of a commissioned pathway for the identification 

















pen: first published as 10.1136/bm









The following definitions are relevant to the KLIFAD trial: 
Recovery Definition 
For the KLIFAD trial we adopted the following definition of “Recovery” 
“A period of sustained abstinence from alcohol creating a deeply personal, unique process of change, 
a way of living a satisfying, hopeful and contributing life even with limitations caused by illness. A 
process involving the development of new meaning or purpose in one’s life which maximises health 
and wellbeing and participation in the rights, roles and responsibilities of society”1-4.  
Recovery story 
A story told by a person about their journey of recovery. 
In KLIFAD we are using recovery stories which are primarily first-person lived experience accounts, 
which include elements of both adversity/struggle and of strength/success/survival related to AUD, 
and which refer to events or actions over a period. Some stories will include brief fragments presenting 
clinical perspectives on a case, provided by a clinician who worked with the narrator5.  
Story narrator  
The person telling their own recovery story. 
Story recipient 
The person viewing, reading or listening to someone else’s recovery story. 
KLIFAD Library 
A collection of recovery stories intended for use in the KLIFAD feasibility trial.  
Alcohol misuse 
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) define alcohol misuse as “alcohol 
consumption that puts individuals at increased risk for adverse health and social consequences”6 
Alcohol use disorders  
The NIAAA define AUD as “a chronic relapsing brain disorder characterized by an impaired ability to 
stop or control alcohol use despite adverse social, occupational, or health consequences” 6. 
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SP-Focus Group Guide WP1 V2.0 
 
Focus group Guide participants 
Work Package 1 (WP1) 
                                                                  Version 2.0 Date:14/10/2020 
Study title: Does knowledge of liver fibrosis affect high-risk drinking behaviour (KLIFAD)? A 
feasibility randomised controlled trial 
To begin 
Welcome to the focus group session. Thanks for taking the time to join us to talk about liver disease 
screening.  
You were invited here today because you attended a liver scan appointment and were given your 
level of risk for liver disease using a Fibroscan machine. We would like to understand how to provide 
the best experience for patients undergoing the scan. This includes how the person operating the 
Fibroscan machine discusses the scan itself and then delivers the results of the scan to patients. We 
will ask you to read through a script we have prepared to help operators talk through the scan and 
also a document that provides patients with their results. 
Everyone’s risk of liver disease may be different. Because everyone has very different life 
experiences, there are no wrong answers to these questions, but rather different points of view. 
Please feel free to share your point of view even if it differs from what others have said. Keep in 
mind that we're just as interested in negative comments as positive comments, and at times the 
negative comments are the most helpful.  
 
Logistics 
• Focus group will last about 2 hours 
• Feel free to move around 
• Where is the bathroom?  Exit? 
• Help yourself to refreshments 
 
Ground Rules  
• Hope that everyone feels comfortable enough to participate. 
• Information provided in the focus group must be kept confidential 
• Stay with the group and please don’t have side conversations 
• Turn off mobile phones if possible 
• This is an opportunity to help contribute to the treatment of liver disease! 
 
You've probably noticed the microphone. I’m tape recording the session because I don't want to 
miss any of your comments. People often say very helpful things in these discussions and I can't 
write fast enough to get them all down. 
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If you talk about anyone else during the focus group by name (such as a friend or member of staff) – 
then we will keep their name anonymous when we write up the results by providing them with a false 
name.  Likewise (the participant) we will also keep your identity anonymous during the write-up by 
giving you a false name in any reports resulting from this study 
 
Are you okay with this? Do you have any questions? 
o Answer any questions they have 
o If they do not want to participate, thank them for their time and escort them out of the 
venue. If they have participated via telephone or over video conferencing – finish the call. 
 
Beginning the focus group 
Start recording the interview on the Dictaphone.  
 
Firstly, I want you to think back to your liver scan appointment.  
1. Did you understand why you were undergoing a fibroscan and what the scan involved? 
2. What was your experience of the scan? Was there anything about the way the operator 
conducted the scan or talked to you about the scan that you liked/disliked/found helpful? 
3. After the scan, what information were you provided with? Including your results, any 
feedback from the scan operator, and any other information about liver disease?  
a. Was any of this difficult to understand? What information did you find most 
helpful? 
4. Did the scan and/or scan results prompt you to make some changes to improve your liver 
health?  
a. If you received normal scan results, did you still want to make lifestyle changes? 
 
 
Now I’d like us to spend the rest of the session today reviewing the documents in front of you. 
Please take some time to read through these documents and write any thoughts you have about the 
wording or how the information is presented on the document.  
 
Provide participants with pens 
Give participants approximately 10-15 minutes to read through script and fibroscan results 
 
Let’s review the operator script. Imagine you were receiving this information from a fibroscan 
operator. 
 
1. Do you understand the information presented in the script?  
a. What did you like/dislike about the script? What information was helpful/unhelpful? 
Was anything unclear?  
2. Was there any information you felt was missing or that you think would make a useful 
addition to the script? 
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a. Do you have any suggested changes or improvements to the script? 
 
Now let’s review the fibroscan result documents. There are three different results a patient can 
receive, depending on their liver stiffness. Imagine you were receiving this information from a 
fibroscan operator. 
 
1. Do you think the results made sense for each level of liver disease stiffness?  
a. Did you understand the information? What information was helpful/unhelpful? Was 
anything unclear? 
2. How did the documents make you feel?  
a. Did anyone have a negative reaction/positive reaction? 
3. Did you like the way the results were presented (e.g. graphically, visually)?  
a. What would you change? Would you prefer the results to be presented as a value, 
on a scale, on a graph etc.? 
4. Would you feel confident knowing what your result was and how to go about making 
lifestyle changes from this information?  
a. If not, why and what could we include that would help improve your confidence? Do 
you think the results documents would need explaining further by the operator? 
5. Does anyone have additional thoughts about a specific result document (normal, likely 
fibrosis, likely cirrhosis)? 
a. Do you think the information reflects the level of risk and need for behaviour 
change? 
6. Is there any other information we should include in the results document?  
a. Do you have any suggested changes or improvements to the results? 
 
Close  
Okay, that reaches the end of the questions I wanted to ask today. Is there anything else you wanted 
to add or talk about that we didn’t talk about today? 
If you’re okay to end the focus group there, I’ll switch the Dictaphone off, thank you!  
 
Debriefing 
• Thank you for speaking to us. 
• Provide participants with a sheet which outlines the range of services etc, go through it with 
them. If there is any particular service/resource that they have expressed an interest in – then 
signpost them to it.  
o If they have participated via telephone– a state that they can be sent this via email if 
this wish or it can be read out to them. 
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SP-Change model questionnaire (CMQ) V1.0 
 
Change model questionnaire 
Work package 1 (WP1) V1.0 26/10/2020 
 
Study title: Does knowledge of liver fibrosis affect high-risk drinking behaviour (KLIFAD)? A 
feasibility randomised controlled trial 
Your doctor may have asked you to cut down how much alcohol you are drinking. 
Please find the statement that best describes the way you feel right now about cutting 
down your alcohol use to the amount the research team recommends  
 
฀ I am continuing to drink at the same level and right now I am not considering 
reducing how much I drink 
 
฀ I am continuing to drink at the same level but and right now I am considering 
reducing how much I drink 
 
฀ I am continuing to drink at the same level but I am planning to reduce how 
much I drink 
 
฀ Right now I have reduced how much alcohol I drink, and have maintained this 
for less than six months  
 
฀ Right now I have reduced how much alcohol I drink, and have maintained this 
for more than six months  
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SP- Qualitative interview guide 
                                                   
                                                   Qualitative interview Guide 
                                            Work package 3 (WP 3) Feasibility RCT  
 
Study title: Does knowledge of liver fibrosis affect high-risk drinking behaviour 
(KLIFAD)? A feasibility randomised controlled trial 
To begin 
• Go over the study information again with the participant: 
o Thank you for coming to/agreeing to take part in the interview today… 
o Explain what will happen:  
o ‘You’ll be asked brief questions about your experience of taking part in the 
KLIFAD study and some questions about how you felt about taking part in this 
study and how it might have had an impact on you”.   
o There are no ‘right’ or ‘wrong’ answers – I am not here to judge you, but to 
listen to your experiences as everyone’s experience is valuable. 
o You can tell us as little or as much information as you want to during this 
interview, it is kept confidential in the research team. We may use a 
transcription service, but they are required to sign a confidentiality agreement 
and identifiers are removed from the typed-up transcript. 
o You can pause or stop the interview at any time if you want a break, you feel 
uncomfortable or don’t want to continue with the interview. 
o After the interview, I will provide you with information about services and 
resources – that you may find useful if you have any concerns about what you 
have told us. 
• Are you okay with all this? Do you have any questions? 
o Answer any questions they have 
o If they do not want to participate, thank them for their time and escort them 
out of the venue. If they have participated via telephone or over video 
conferencing – finish the call. 
 
• Note: We will ask our PPI group about whether to include clarification of specific terms 
at this point. For example, relapse or lapse or teetotal/sober etc to ensure we ask 
questions in the participant’s preferred way of talking about their alcohol use. 
• If you talk about anyone else during the interview by name (such as a friend or member 
of staff) – then we will keep their name anonymous when we write up the results by 
providing them with a false name.  Likewise (the participant) we will also keep your 
identity anonymous during the write-up by giving you a false name in any reports 
resulting from this study 
• If you are satisfied with this, please confirm that you still consent to take part. 
o They will have already consented to take part when they signed up. Check you 
have received this consent (if was by e-mail or post). 
o If unsatisfied and does not want to take part – thank them for their time and 
guide them out of the venue/end the call. 
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Beginning the interview 
Start recording the interview on the Dictaphone.  
Here we can ask an introductory question to establish some rapport.  
 
Your experience of the KLIFAD study 
 
Q. Have you ever taken part in a research study before?  
 
Q. Can you take me through what you remember about the KLIFAD study? (If they get 
into specifics of the results…. We’ll touch on that later, for now, I’d like you to think about 
your experience of the scan process as a whole, for example how you felt about the scan 
or the staff who scanned you.) 
 
Q. Overall, how do you feel about taking part in the KLIFAD study?  
Follow up questions: If positive feedback: What did you particularly like? 
If negative feedback: What did you not like/thought could be different? 
 
Q. In regard to the fibroscan, did you understand why you were invited to have this scan? 
Did the staff give you enough information about the scan? Was there anything about the 
whole process you liked/didn’t like? 
 
Q. Where did you watch the stories? Did you watch it with anyone else? What was your 
response to them?  
 
Your feelings about getting the KLIFAD study 
 
Q. Can you tell me what you remember about your fibroscan scan result? 
Follow-up questions: Can you remember the specific value, scale, what the value meant 
(potential liver disease etc)? Was the result explained clearly, did you understand it? Can 
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you think of ways to improve how we give people their scan results? Is there anything else 
you think would be helpful to know when you receive your scan result? 
 
Q. Do you remember how you felt when you first got your fibroscan result? Explore their 
thoughts and feelings here by using reflection ‘So, I’m hearing that you felt confused and 
a bit frightened’. Also can use follow-up questions if appropriate e.g., Can you talk a bit 
more about why you felt scared? Can you describe your feeling of relief? Etc. 
 
Q. What did it feel like watch stories describing other people’s experiences of receiving a 
fibroscan? Follow up questions: Which stories can you remember accessing? Can you 
describe any ways in which these made an immediate impact on you? Can you describe 
any ways in which these have made a longer-tem impact on you? Did you learn anything 
from the stories? 
 
Q. Did you discuss the KLIFAD study with anyone?  
Follow up questions: What part did you talk about? (Scan/story/both?). Who did you talk 
to about it? How did they feel about it? If they didn’t talk to anyone about it, ask why they 
didn’t 
 
Q. Now that a bit of time has passed, how do you feel about taking part in the KLIFAD 
study?  
 
Your use of alcohol since you took part in the KLIFAD study 
 
Q. Can you talk about your use of alcohol at a few different time points? It may be hard 
to remember this far back so sometimes it’s helpful to look at a calendar and plot out some 
key dates (e.g. birthdays, trips away) that can help you remember.  
 
1. Your use of alcohol (if any) just before you had your fibroscan result 
2. Your use of alcohol (if any) on the day or days after you had your fibroscan result 
3. Your use of alcohol (if any) two weeks after you had your result 
4. Your use of alcohol (if any) over the last month 
 
Q. Do you think the KLIFAD study changed your use of alcohol in any way?  
If yes: explore, how, why do they think it affected it. If no: invite them to talk about that. 
Explore if they sought out additional supports e.g. AA 
Follow-up: Had you thought about changing before taking part in this study?  
 
Q. If yes to changes, what were your main reasons for making these changes? 
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Q. If no, tell me more about why you didn’t want to or didn’t feel able to make changes at 
that time. 
Follow-up questions: Was there anything that helped you make the changes? Was there 
anything that was a barrier to making changes? 
 
Close  
Okay that reaches the end of the questions I wanted to ask you. Is there anything else 
you wanted to add or talk about that we didn’t talk about today? 
If you’re okay to end the interview there, I’ll switch the Dictaphone off, thank you!  
 
Debriefing 
• Thank you for speaking to us. 
• How are you feeling – is there anything in the interview has troubled you or upset 
you? 
• Provide participant with sheet which outlines range of services etc, go through it 
with them. If there is any particular service/resource that they have expressed an 
interest in – then signpost them to it.  
o If they have participated via telephone– state that they can be sent this via 
email if this wish or it can be read out to them. 
• Thank them again, and ask if they are feeling okay to leave the building/ or hang 
up/exit the call.  
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